Respiratory Syncytial Virus Infections

Open Access

Antiviral Agents
Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor
Matthew Coates, Daniel Brookes, Young-In Kim, Heather Allen, Euan A. F. Fordyce, Elizabeth A. Meals, Thomas Colley, Claire-Lise Ciana, Guillaume F. Parra, Vladimir Sherbukhin, Jennifer A. Stockwell, Jennifer C. Thomas, S. Fraser Hunt, Lauren Anderson-Dring, Stuart T. Onions, Lindsey Cass, Peter J. Murray, Kazuhiro Ito, Pete Strong, John P. DeVincenzo, Garth Rapeport
Open Access

Antiviral Agents
A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading
Vanessa Gaillard, Marie Galloux, Dominique Garcin, Jean-François Eléouët, Ronan Le Goffic, Thibaut Larcher, Marie-Anne Rameix-Welti, Abdelhak Boukadiri, Julien Héritier, Jean-Manuel Segura, Elodie Baechler, Miriam Arrell, Geneviève Mottet-Osman, Origène Nyanguile
Open Access

Antiviral Agents
Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults
M. Pamela Griffin, Anis A. Khan, Mark T. Esser, Kathryn Jensen, Therese Takas, Martin K. Kankam, Tonya Villafana, Filip Dubovsky
Pharmacology
Pharmacokinetics-Pharmacodynamics of a Respiratory Syncytial Virus Fusion Inhibitor in the Cotton Rat Model
Marie-Claude Rouan, Tom Gevers, Dirk Roymans, Loeckie de Zwart, David Nauwelaers, Marc De Meulder, Pieter van Remoortere, Marc Vanstockem, Anil Koul, Kenny Simmen, Koen Andries
Antiviral Agents
RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral Strategy
Rene Alvarez, Sayda Elbashir, Todd Borland, Ivanka Toudjarska, Philipp Hadwiger, Mathias John, Ingo Roehl, Svetlana Shulga Morskaya, Rick Martinello, Jeffrey Kahn, Mark Van Ranst, Ralph A. Tripp, John P. DeVincenzo, Rajendra Pandey, Martin Maier, Lubomir Nechev, Muthiah Manoharan, Victor Kotelianski, Rachel Meyers
Experimental Therapeutics
Comparative Effects of Two Neutralizing Anti-Respiratory Syncytial Virus (RSV) Monoclonal Antibodies in the RSV Murine Model: Time versus Potency
Asunción Mejías, Susana Chávez-Bueno, Ana María Ríos, Mónica Fonseca Aten, Brett Raynor, Estrella Peromingo, Perla Soni, Kurt D. Olsen, Peter A. Kiener, Ana María Gómez, Hasan S. Jafri, Octavio Ramilo
Antiviral Agents
Oral Efficacy of a Respiratory Syncytial Virus Inhibitor in Rodent Models of Infection
Christopher Cianci, Eugene V. Genovesi, Lucinda Lamb, Ivette Medina, Zheng Yang, Lisa Zadjura, Hyekyung Yang, Celia D'Arienzo, Ny Sin, Kuo-Long Yu, Keith Combrink, Zhufang Li, Richard Colonno, Nicholas Meanwell, Junius Clark, Mark Krystal
Experimental Therapeutics
Anti-Respiratory Syncytial Virus (RSV) Neutralizing Antibody Decreases Lung Inflammation, Airway Obstruction, and Airway Hyperresponsiveness in a Murine RSV Model
Asunción Mejías, Susana Chávez-Bueno, Ana María Ríos, Jesús Saavedra-Lozano, Mónica Fonseca Aten, Jeanine Hatfield, Payal Kapur, Ana María Gómez, Hasan S. Jafri, Octavio Ramilo
Antiviral Agents
Comparison of Corticosteroids for Treatment of Respiratory Syncytial Virus Bronchiolitis and Pneumonia in Cotton Rats
Martin G. Ottolini, Spencer J. Curtis, David D. Porter, Amy Mathews, Joann Y. Richardson, Val G. Hemming, Gregory A. Prince
Antiviral Agents
Antiviral Activity of Lovastatin against Respiratory Syncytial Virus In Vivo and In Vitro
Tara L. Gower, Barney S. Graham

Main menu

User menu

Search

Respiratory Syncytial Virus Infections

Pages